Refractory Chronic Lymphocytic Leukemia
Showing NaN - NaN of 12
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +7 more
- Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jul 14, 2022
Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma Trial in United
Recruiting
- Relapsed Chronic Lymphocytic Leukemia
- +4 more
-
Phoenix, Arizona
- +7 more
Apr 28, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of
Active, not recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +22 more
- Ibrutinib
- +3 more
-
Scottsdale, Arizona
- +1 more
Aug 10, 2021
B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Stage 0 Chronic Lymphocytic Leukemia Trial in
Completed
- B-cell Chronic Lymphocytic Leukemia
- +4 more
- alemtuzumab
- +9 more
-
Rochester, MinnesotaMayo Clinic
Jun 11, 2020
Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Denmark, Italy, United
Completed
- Chronic Lymphocytic Leukemia
- +8 more
- Allogeneic Hematopoietic Stem Cell Transplantation
- +8 more
-
Rochester, Minnesota
- +4 more
Jun 20, 2019
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Grade 1
Completed
- Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- +8 more
- Bortezomib
- +5 more
-
Scottsdale, Arizona
- +1 more
Apr 4, 2019
Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in United
Completed
- Chronic Lymphocytic Leukemia
- +2 more
- Akt Inhibitor MK2206
- +3 more
-
Scottsdale, Arizona
- +43 more
Aug 17, 2017
B-cell Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in
Completed
- B-cell Chronic Lymphocytic Leukemia
- +2 more
- sunitinib malate
- +2 more
-
Rochester, MinnesotaNorth Central Cancer Treatment Group
Apr 28, 2014
B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia Trial in Rochester (bevacizumab)
Completed
- B-cell Chronic Lymphocytic Leukemia
- Refractory Chronic Lymphocytic Leukemia
- bevacizumab
-
Rochester, MinnesotaMayo Clinic
Apr 21, 2014
B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia Trial in Rochester (thalidomide, laboratory
Completed
- B-cell Chronic Lymphocytic Leukemia
- Refractory Chronic Lymphocytic Leukemia
- thalidomide
- laboratory biomarker analysis
-
Rochester, MinnesotaNorth Central Cancer Treatment Group
Oct 7, 2013
Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Stage III Multiple Myeloma Trial in Rochester
Completed
- Refractory Chronic Lymphocytic Leukemia
- +4 more
- 17-N-allylamino-17-demethoxygeldanamycin/bortezomib
- sorafenib tosylate
-
Rochester, MinnesotaMayo Clinic
Mar 18, 2013
B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia Trial in Rochester (cediranib maleate, laboratory
Completed
- B-cell Chronic Lymphocytic Leukemia
- Refractory Chronic Lymphocytic Leukemia
- cediranib maleate
- laboratory biomarker analysis
-
Rochester, MinnesotaNorth Central Cancer Treatment Group
Jan 14, 2013